EX-99.1 2 dp15253_ex9901.htm EXHIBIT 99.1
Exhibit 99.01
 
Press Release
www.shire.com
 
Notification of major interests in shares
 
October 15, 2009 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company
 
 
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
 
Shire plc
 
2. Reason for the notification
State
Yes/No
An acquisition or disposal of voting rights
Yes
An acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached
     
An event changing the breakdown of voting rights
  
Other (please specify):      
     
 

 
3. Full name of person(s) subject to the notification obligation:
Legal & General Group Plc (L&G)
4. Full name of shareholder(s) (if different from 3.):
Legal & General Assurance (Pensions Management) Limited (PMC)
5. Date of the transaction (and date on which the threshold is crossed
or reached if different):
13 October 2009
6. Date on which issuer notified:
14 October 2009
7. Threshold(s) that is/are crossed or reached:
From 4% - 3% (L&G)
8. Notified details:
     
 
A: Voting rights attached to shares
 
Class/type of shares
if possible using the ISIN CODE
Situation previous to
the Triggering
transaction
Resulting situation after the triggering
transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of
shares
Number of voting
rights
% of voting
rights
       
Direct
Indirect
Direct
Indirect
ORD
GBP 0.05
22,869,115
22,869,115
22,269,735
22,269,735
  
3.96
  
 
 
 
B: Qualifying Financial Instruments
 
Resulting situation after the triggering transaction
 
Type of financial
instrument
Expiration
date
Exercise/Conversion
Period/ Date
Number of voting
rights that may be
acquired if the instrument
is exercised/converted
% of voting
rights
         
 

 
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
 
Resulting situation after the triggering transaction
 
Type of financial
instrument
Exercise
price
Expiration
date
Exercise/
Conversion
period
Number of voting
rights instrument
refers to
% of voting rights
         
Nominal
Delta
   
 

 
Total (A+B)
  
Number of voting rights
% of voting rights
22,269,735
3.96
 
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
 
     
Legal & General Group Plc (Direct and Indirect) (Group)
  
   
Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect)
  
   
Legal & General Investment Management Limited (Indirect) (LGIM)
  
   
Legal & General Group Plc (Direct) (L&G) (22,269,735 –3.96 % = LGAS, LGPL & PMC)
 
Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD) (20,267,101 –3.61 % = PMC)
Legal & General Insurance Holdings Limited (Direct) (LGIH)
   
Legal & General Assurance (Pensions Management) Limited (PMC) (20,267,101 –3.61 % = PMC)
Legal & General Assurance Society Limited (LGAS & LGPL)
   
 
Legal & General Pensions Limited (Direct) (LGPL)
 
 
 
 

Proxy Voting:
 
10. Name of the proxy holder:
N/A
11. Number of voting rights proxy holder will cease to hold:
N/A
12. Date on which proxy holder will cease to hold voting rights:
N/A
 

 
13. Additional information:
Notification using the total voting rights figures of 561,047,527
14. Contact name:
Helen Lewis (LGIM)
15. Contact telephone number:
020 3124 3851
 
Contact at Shire plc: Tony Guthrie, Deputy Company Secretary, 01256 894746
 
 
For further information please contact:
 
Investor Relations
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
     
 
Eric Rojas (North America)
+1 617 551 9715
 
Notes to editors
 
 
SHIRE PLC
 
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
 
 
For further information on Shire, please visit the Company’s website: www.shire.com.